Valproic acid restores ERα and antiestrogen sensitivity to ERα-negative breast cancer cells

Molecular and Cellular Endocrinology

Volumn 314, Issue 1, 2010, Pages 17-22

  Fortunati, N ^a   Bertino, S ^b   Costantino, L ^b   De Bortoli, M ^b   Compagnone, A ^b   Bandino, A ^b   Catalano, M G ^b   Boccuzzi, G ^a,b  

^a Oncological Endocrinology   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Antiestrogen; Breast cancer; ER ; HDI; VPA

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN PS2; TAMOXIFEN; VALPROIC ACID;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; TAMOXIFEN; TRANSCRIPTION, GENETIC; VALPROIC ACID;

EID: 70350303309     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.09.011     Document Type: Article

References (31)

1. Badve S., Turbin D., Thorat M.A., Morimiya A., Nielsen T.O., Perou C.M., Dunn S., Huntsman D.G., and Nakshatri H. FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin. Cancer Res. 13 (2007) 4415-4421
2. Biçaku E., Marchion D.C., Schimitt M.L., and Münster P. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signalling. Cancer Res. 68 (2008) 1513-1519
3. Carroll J.S., and Brown M. Estrogen receptor target gene: an evolving concept. Mol. Endocrinol. 20 (2006) 1707-1714
4. Carroll J.S., Liu X.S., Brodsky Li W., Meyer C.A., Szary A.J., Eeckhoute J., Shao W., Hestermann E.V., Geistlinger T.R., Fox E.A., Silver P.A., and Brown M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122 (2005) 33-43
5. Catalano M.G., Poli R., Pugliese M., Fortunati N., and Boccuzzi G. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr. Relat. Cancer 14 (2007) 839-845
6. Chapman A., Keane P.E., Meldrum B.S., Simiand J., and Vernieres J.C. Mechanism of anticonvulsant action of valproate. Prog. Neurobiol. 19 (1982) 315-359
7. Cicatiello L., Scafoglio C., Altucci L., Cancemi M., Natoli G., Facchiano A., Iazzetti G., Calogero R., Biglia N., De Bortoli M., Sfiligoi C., Sismondi P., Bresciani F., and Weisz A. A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J. Mol. Endocrinol. 32 (2004) 719-775
8. Clarke R., Skaar T.C., Bouker K.B., Davis N., Lee Y.R., Welch J.N., and Leonessa F. Molecular and pharmacological aspects of antiestrogen resistance. J. Steroid Biochem. Mol. Biol. 76 (2001) 71-84
9. De los Santos M., Martinez-Iglesias O., and Aranda A. Anti-estrogenic actions of histone deacetylase inhbitors in MCF-7 breast cancer cells. Endocr. Relat. Cancer 14 (2007) 1021-1028
10. DeVane C.L. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol. Bull. 37 (2003) 25-42
11. Fortunati N., Bertino S., Costantino L., Bosco O., Vercellinatto I., Catalano M.G., and Boccuzzi G. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett. 259 (2008) 156-164
12. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., and Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20 (2001) 6969-6978
13. Hodges-Gallagher L., Valentine C.D., Bader S.E., and Kushner P.J. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res. Treat. 105 (2007) 297-309
14. Katzenellenbogen B.S., and Frasor J. Therapeutic targeting in the estrogen receptor hormonal pathway. Semin. Oncol. 31 (2004) 28-38
15. Keen J.C., Yan L., Mack K.M., Pettit C., Smith D., Sharma D., and Davidson N.E. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res. Treat. 81 (2003) 177-186
16. Kininis M., and Kraus W.L. A global view of transcriptional regulation by nuclear receptors: gene expression, factor localization, and DNA sequence analysis. Nucl. Recept. Signal. 6 (2008) e005
17. Laganière J., Deblois G., Lefebvre C., Bataille A.R., Robert F., and Giguère V. From the cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 11651-11656
18. Lapidus R.G., Nass S.J., Butash K.A., Parl F.F., Weitzman S.A., Graff J.G., Herman J.G., and Davidson N.E. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res. 58 (1998) 2515-2519
19. Lupien M., Eeckhoute J., Meyer C.A., Wang Q., Zhang Y., Li W., Carroll J.S., Liu X.S., and Brown M. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132 (2008) 958-970
20. Osborne C.K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339 (1998) 1609-1618
21. Ottaviano Y.L., Issa J.P., Parl F.F., Smith H.S., Baylin S.B., and Davidson N.E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54 (1994) 2552-2555
22. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276 (2001) 36734-36741
23. Ring A., and Dowsett M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11 (2004) 643-658
24. Robyr D., Gegonne A., Wolffe A.P., and Wahali W. Determinants of vitellogenin B1 promoter architecture, HNF3 and estrogen responsive transcription within chromatin. J. Biol. Chem. 275 (2000) 28291-28300
25. Scafoglio C., Ambrosino C., Cicatiello L., Altucci L., Ardovino M., Bontempo P., Medici N., Molinari A.M., Nebbioso A., Facchiano A., Calogero R.A., Elkon R., Menini N., Ponzone R., Biglia N., Sismondi P., De Bortoli M., and Weisz A. Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J. Cell Biochem. 98 (2006) 1163-1184
26. Sharma D., Saxena N.K., Davidson N.E., and Vertino P.M. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 66 (2006) 6370-6378
27. Thorat M.A., Marchio C., Morimiya A., Savage K., Nakshatri H., Reis-Filho J.S., and Badve S. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J. Clin. Pathol. 61 (2008) 327-332
28. Yamaguchi N., Ito E., Azuma A., Honma R., Yanagisawa Y., Nishikawa A., Kawamura M., Imai J., Tatsuta K., Inoue J., Semba K., and Watanabe S. FoxA1 as a lineage-specific oncogene in luminal type breast cancer. Biochem. Biophys. Res. Commun. 365 (2008) 711-717
29. Yang X., Ferguson A.T., Nass S.J., Phillips D.L., Butash K.A., Wanf S.M., Herman J.G., and Davidson N.E. Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 60 (2000) 6890-6894
30. Yang X., Phillips D.L., Ferguson A.T., Nelson W.G., Herman J.G., and Davidson N.E. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 61 (2001) 7025-7029
31. Zhou Q., Atadja P., and Davidson N.E. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol. Ther. 6 (2007) 64-69